Immunovant, Inc. Common Stock vs. Tarsus Pharmaceuticals, Inc. Common Stock
IMVT
Immunovant, Inc. Common Stock
$40.93 +2.61%
VS TARSTarsus Pharmaceuticals, Inc. Common Stock
$69.46 +2.51%
Immunovant, Inc. Common Stock (IMVT) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| IMVT | TARS | |
|---|---|---|
| Market Cap | $8.45 billion | $3.05 billion |
| Net Income (TTM) | $-538,217,000 | — |
IMVT leads on 1 of 1 size & scale factors.
Valuation
| IMVT | TARS | |
|---|---|---|
| Price / Book | 11.50 | — |
IMVT and TARS split the valuation factors evenly.
Profitability
| IMVT | TARS | |
|---|---|---|
| Return on Equity | -73.19% | — |
IMVT and TARS split the profitability factors evenly.
Risk & Sentiment
| IMVT | TARS | |
|---|---|---|
| Short Interest | 0.15% | 0.31% |
IMVT leads on 1 of 1 risk & sentiment factors.
Dig deeper: IMVT overview, IMVT financials, TARS overview, TARS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.